Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

15.51
+0.98006.74%
Post-market: 15.510.00000.00%19:30 EDT
Volume:1.16M
Turnover:17.50M
Market Cap:998.14M
PE:-4.47
High:15.56
Open:14.76
Low:14.59
Close:14.53
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.96
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:3.10
PE(LYR):-4.17

Loading ...

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)

TIPRANKS
·
Yesterday

Cullinan Therapeutics Price Target Maintained with a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Cullinan Management Advances NDA for Zipalertinib Combination

TIPRANKS
·
Yesterday

Cullinan Initiates FDA NDA Submission for Zipalertinib Plus Chemotherapy Under RTOR Program

Reuters
·
Yesterday

Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer

MT Newswires Live
·
Yesterday

Cullinan Therapeutics initiates NDA for Zipalertinib

TIPRANKS
·
Yesterday

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line Egfr Exon 20 Insertion Mutation Nsclc for Review Under FDA Real-Time Oncology Review Program

THOMSON REUTERS
·
Yesterday

Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Cullinan Management (CGEM)

TIPRANKS
·
Sep 25

Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright

TIPRANKS
·
Sep 25

Cullinan Therapeutics Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts

TIPRANKS
·
Sep 25

Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen

TIPRANKS
·
Sep 25

Cullinan falls after pushing rheumatoid arthritis data to December

TIPRANKS
·
Sep 24

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

GlobeNewswire
·
Sep 24

Small U.S. Stocks Close Lower; Cullinan Therapeutics Posts Biggest Loss

Dow Jones
·
Sep 24

Cullinan Therapeutics Down over 20%, on Track for Record Percent Decrease

Dow Jones
·
Sep 24

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

GlobeNewswire
·
Sep 22

Cullinan Management (CGEM) Gets a Buy from Wedbush

TIPRANKS
·
Sep 15

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), High Tide (HITI) and Cullinan Management (CGEM)

TIPRANKS
·
Sep 15